Cidara Therapeutics, Inc. Income Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations and Comprehensive Loss

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenues:
Collaboration revenue
Product revenue
Total revenues
Operating expenses:
Cost of product revenue
Acquired in-process research and development
Research and development
Selling, general and administrative
General and administrative
Total operating expenses
Loss from operations
Other income, net:
Change in fair value of contingent forward purchase obligation
Interest income, net
Other expense
Total other income, net

Net loss from continuing operations before income tax expense
Income tax expense
Net loss from continuing operations
Income from discontinued operations (including loss on disposal of discontinued operations of $1,799 and zero during the years ended December 31, 2024 and 2023, respectively), net of income taxes
Net loss and comprehensive loss
Net loss attributable to common shareholders
Basic and diluted net loss per common share (USD per share)
Shares used to compute basic and diluted net loss per common share (in shares)
Unrealized gain on short-term investments
Basic net loss per common share from continuing operations (USD per share)
Diluted net loss per common share from continuing operations (USD per share)
Basic net earnings per common share from discontinued operations (USD per share)
Diluted net earnings per common share from discontinued operations (USD per share)
Basic net loss per common share (USD per share)
Diluted net loss per common share (USD per share)
Shares used to compute basic net earnings (loss) per common share (in shares)
Shares used to compute diluted net earnings (loss) per common share (in shares)

Comments